Age Differences Seen in Efficacy of Type 2 Diabetes Treatments

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 11, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, Feb. 11, 2025 -- Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in the Journal of the American Medical Association.

Peter Hanlon, Ph.D., from the University of Glasgow in the United Kingdom, and colleagues reviewed the literature to examine whether age or sex is associated with differences in the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors. Individual participant data were obtained for 103 trials: 103 reported hemoglobin A1c (HbA1c), and six reported major adverse cardiovascular events (MACEs).

The researchers found that compared with placebo, SGLT2 inhibitor use was associated with less HbA1c lowering with increasing age for monotherapy, dual therapy, and triple therapy (absolute reductions, 0.24, 0.17, and 0.25 percent, respectively, per 30-year increment in age). GLP-1 receptor agonist use was associated with greater HbA1c lowering with increasing age for monotherapy and dual therapy (absolute reductions, –0.18 and –0.24 percent) but not for triple therapy. Slightly better HbA1c lowering was seen in association with DPP4 inhibitor use in older people for dual therapy (absolute reduction, –0.09 percent) but not for monotherapy or triple therapy. The relative reduction in MACEs with SGLT2 use was greater in older versus younger participants, while the relative reduction with GLP-1 receptor agonist use was less in older versus younger participants. Sex was not associated with differences in efficacy for any of the diabetes treatments studied.

"For hemoglobin A1c, use of SGLT2 inhibitors showed modestly reduced efficacy with increasing age," the authors write. "In contrast, the reduction in major adverse cardiovascular events with SGLT2 inhibitors was greater in older people compared with younger people."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-12 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords